Kaiyue Feng

Title: Innovations of Kaiyue Feng in Atrial Fibrillation Treatment

Introduction

Kaiyue Feng is an accomplished inventor based in Xi'an, China. He has made significant contributions to the field of medical science, particularly in the treatment of atrial fibrillation. His innovative work has led to the development of a unique polypeptide composition that holds promise for patients suffering from this condition.

Latest Patents

Feng's most notable patent is titled "Long-acting polypeptide composition for treating atrial fibrillation and its application." This patent describes a polypeptide composition that includes a specific sequence: fADNYTRLRKQMAVKKYLNSILN-NH(SEQ ID NO: 1). The composition features a first amino acid (f) as D-Phe, a second amino acid as Ala, and a third amino acid as Asp. Notably, the peptide is linear in a solution and forms an α-helix structure upon encountering a lipid bilayer. This innovative approach could enhance the effectiveness of treatments for atrial fibrillation.

Career Highlights

Kaiyue Feng is affiliated with The First Affiliated Hospital of Xi'an Jiao Tong University, where he conducts his research and development work. His dedication to advancing medical treatments has positioned him as a key figure in his field. Feng's work is characterized by a commitment to improving patient outcomes through innovative solutions.

Collaborations

Feng collaborates with esteemed colleagues, including Yue Wu and Chaofeng Sun. These partnerships enhance the research environment and foster the exchange of ideas, contributing to the advancement of their collective work in medical science.

Conclusion

Kaiyue Feng's contributions to the treatment of atrial fibrillation through his innovative polypeptide composition exemplify the impact of dedicated research in medicine. His work not only showcases his inventiveness but also holds the potential to improve the lives of many patients.